Integrated Wealth Concepts LLC Has $3.19 Million Stock Holdings in Exelixis, Inc. $EXEL

Key Points

• Integrated Wealth Concepts LLC reduced its Exelixis position by 25.7% in the second quarter, selling 20,265 shares and retaining 58,636 shares valued at approximately $3.19 million.
• Exelixis reported quarterly earnings of $0.91 per share, beating estimates of $0.85, while revenue rose 10.6% year over year to $628.69 million. Institutional investors own approximately 85.27% of the company.
• Analyst sentiment is mixed, with a consensus rating of “Hold” and an average price target of $50.07. Separately, the FDA extended its review of zanzalintinib for metastatic colorectal cancer by three months, delaying a decision until March 2027.

Integrated Wealth Concepts LLC reduced its position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 25.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 58,636 shares of the biotechnology company's stock after selling 20,265 shares during the period. Integrated Wealth Concepts LLC's holdings in Exelixis were worth $3,190,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in EXEL. BlackRock Inc. bought a new position in shares of Exelixis in the 2nd quarter valued at $1,581,991,000. California State Teachers Retirement System lifted its position in shares of Exelixis by 4,875.6% during the 2nd quarter. California State Teachers Retirement System now owns 14,785,373 shares of the biotechnology company's stock worth $804,472,000 after buying an additional 14,488,217 shares during the last quarter. AQR Capital Management LLC lifted its position in shares of Exelixis by 48.8% during the 4th quarter. AQR Capital Management LLC now owns 13,658,388 shares of the biotechnology company's stock worth $598,647,000 after buying an additional 4,477,029 shares during the last quarter. Invesco Ltd. boosted its stake in Exelixis by 1.6% in the fourth quarter. Invesco Ltd. now owns 6,054,743 shares of the biotechnology company's stock valued at $265,379,000 after buying an additional 94,218 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Exelixis by 0.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 4,299,597 shares of the biotechnology company's stock valued at $184,391,000 after purchasing an additional 39,920 shares in the last quarter. 85.27% of the stock is currently owned by institutional investors.

Exelixis Stock Performance

EXEL stock opened at $56.12 on Monday. The stock has a market cap of $13.91 billion, a P/E ratio of 17.65, a P/E/G ratio of 1.67 and a beta of 0.42. The stock's fifty day simple moving average is $55.35 and its two-hundred day simple moving average is $50.02. Exelixis, Inc. has a 1-year low of $33.76 and a 1-year high of $59.72.

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.85 by $0.06. Exelixis had a net margin of 35.33% and a return on equity of 42.17%. The business had revenue of $628.69 million for the quarter, compared to analyst estimates of $636.40 million. During the same quarter in the previous year, the firm posted $0.75 earnings per share. The company's revenue for the quarter was up 10.6% on a year-over-year basis. As a group, analysts forecast that Exelixis, Inc. will post 3.19 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Mary Beckerle sold 9,812 shares of the business's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $53.66, for a total value of $526,511.92. Following the sale, the director directly owned 16,079 shares in the company, valued at approximately $862,799.14. The trade was a 37.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 2.60% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Barclays boosted their price objective on Exelixis from $45.00 to $49.00 and gave the stock an "equal weight" rating in a research report on Tuesday, July 14th. HC Wainwright reaffirmed a "buy" rating and issued a $56.00 price objective on shares of Exelixis in a research note on Thursday, July 2nd. BMO Capital Markets initiated coverage on Exelixis in a research note on Tuesday, August 18th. They set a "market perform" rating and a $54.00 target price for the company. William Blair restated an "outperform" rating on shares of Exelixis in a report on Friday. Finally, Wall Street Zen downgraded Exelixis from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $50.07.

Exelixis News Summary

Here are the key news stories impacting Exelixis this week:

• Neutral Sentiment: The FDA extended its review of Exelixis’ application for zanzalintinib in combination with atezolizumab for patients with metastatic colorectal cancer by three months. The new decision target is March 2027. The extension does not indicate a rejection, but it delays regulatory clarity. U.S. FDA extends review of Exelixis' cancer drug
• Negative Sentiment: The delayed decision pushes back the potential launch and commercial ramp of zanzalintinib in colorectal cancer, reducing near-term visibility for investors and contributing to concern about Exelixis’ revenue outlook. Analysts are also assessing the effect of the announcement on stock volatility. Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In
• Neutral Sentiment: The FDA action follows Exelixis’ broader investor presentation and legal developments, but the reports provide no new change to the company’s existing earnings outlook or indication of a problem with its currently marketed products. Exelixis Presents at Citigroup's Biopharma Back to School Summit 2026

Exelixis Company Profile

Exelixis, Inc NASDAQ: EXEL is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. The company's research and development activities center on targeted therapies designed to address biological pathways involved in tumor growth and progression.

Exelixis' principal product is cabozantinib, marketed in the United States as CABOMETYX tablets for certain patients with advanced renal cell carcinoma, hepatocellular carcinoma and radioactive iodine-refractory differentiated thyroid cancer.

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.